# Galectin Therapeutics Inc: overview GALT · Nasdaq · CIK 1133416 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/galt.md) · [Financials](/companies/galt/financials.md) · [Filings](/companies/galt/filings.md) · [Insiders](/companies/galt/insiders.md) Revenue is not reported in this company’s XBRL financial statements. ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.18)](/filings/0001140361-25-042116.md) | not reported | [(0.15)](/filings/0001140361-26-021495.md) | [(0.12)](/filings/0001140361-26-032945.md) | [(0.13)](/filings/0001140361-25-042116.md) | not reported | [(0.08)](/filings/0001140361-26-021495.md) | [(0.14)](/filings/0001140361-26-032945.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.52)](/filings/0001140361-23-014658.md) | [(0.65)](/filings/0001140361-24-016452.md) | [(0.74)](/filings/0001140361-25-011169.md) | [(0.76)](/filings/0001140361-26-012155.md) | [(0.48)](/filings/0001140361-26-012155.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/galt/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $13.9m | 2,988,353 | | Added +2,189,116 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $10.1m | 2,168,065 | | Added +201,523 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $6.1m | 1,308,394 | | Added +695,608 | | [OSAIC HOLDINGS, INC.](/funds/1677044.md) | 2026-06-30 | $5.6m | 1,203,725 | | Added +81,055 | | [MARSHALL WACE, LLP](/funds/1318757.md) | 2026-06-30 | $3.9m | 831,010 | | Reduced −388,902 | | [GREAT POINT PARTNERS LLC](/funds/1281446.md) | 2026-06-30 | $3.7m | 800,000 | Call | Unchanged | | [Wealthspire Advisors, LLC](/funds/1646247.md) | 2026-06-30 | $3.3m | 721,788 | | Unchanged | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $2.6m | 567,779 | | Added +309,347 | | [COMMONWEALTH EQUITY SERVICES, LLC](/funds/312272.md) | 2026-06-30 | $1.9m | 407,113 | | Added +40,000 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $1.8m | 386,545 | | Added +256,097 | ## Recent filings [All 1,244 filings](/companies/galt/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-13 | 12:00 ET | [DEF 14A](/filings/0001140361-26-039379.md) | Proxy statement, period 2026-12-03 | 0001140361-26-039379 | | 2026-08-14 | 11:55 ET | [8-K](/filings/0001140361-26-032946.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-032946 | | 2026-08-14 | 11:51 ET | [10-Q](/filings/0001140361-26-032945.md) | Quarterly report, period 2026-06-30 | 0001140361-26-032945 | | 2026-08-04 | 12:30 ET | [SCHEDULE 13D/A](/filings/0001140361-26-031060.md) | Ownership report, active investor, amended | 0001140361-26-031060 | | 2026-08-04 | 11:50 ET | [8-K](/filings/0001140361-26-031058.md) | 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001140361-26-031058 | | 2026-06-23 | 11:51 ET | [8-K](/filings/0001140361-26-026031.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-026031 | | 2026-05-15 | 11:50 ET | [8-K](/filings/0001140361-26-021496.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-021496 | | 2026-05-15 | 11:46 ET | [10-Q](/filings/0001140361-26-021495.md) | Quarterly report, period 2026-03-31 | 0001140361-26-021495 | | 2026-03-31 | 11:55 ET | [8-K](/filings/0001140361-26-012158.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-012158 | | 2026-03-31 | 11:50 ET | [10-K](/filings/0001140361-26-012155.md) | Annual report, period 2025-12-31 | 0001140361-26-012155 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001140361-26-012155.md), filed Mar 31, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1133416 - Tickers: GALT - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: NV - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.